Adaptimmune Therapeutics (ADAP) Short Interest Ratio & Short Volume $0.06 0.00 (-1.87%) Closing price 04:00 PM EasternExtended Trading$0.06 0.00 (-2.08%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Adaptimmune Therapeutics Short Interest DataAdaptimmune Therapeutics (ADAP) has a short interest of 11.07 million shares. This marks a 32.57% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 13.71 million shares to cover all short positions.Current Short Interest11,070,000 sharesPrevious Short Interest8,350,000 sharesChange Vs. Previous Month+32.57%Dollar Volume Sold Short$658.67 thousandShort Interest Ratio0.4 Days to CoverLast Record DateAugust 15, 2025Outstanding Shares265,050,000 sharesPercentage of Shares Shorted4.18%Today's Trading Volume24,979,995 sharesAverage Trading Volume13,705,673 sharesToday's Volume Vs. Average182% Short Selling Adaptimmune Therapeutics? Sign up to receive the latest short interest report for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartADAP Short Interest Over TimeADAP Days to Cover Over TimeADAP Percentage of Float Shorted Over Time Adaptimmune Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/15/202511,070,000 shares $658.67 thousand +32.6%N/A0.4 $0.06 7/31/20258,350,000 shares $670.51 thousand +115.2%3.6%0.5 $0.08 7/15/20253,880,000 shares $1.06 million -8.9%N/A4 $0.27 6/30/20254,260,000 shares $1.02 million -6.6%1.8%4.2 $0.24 6/15/20254,560,000 shares $1.10 million -14.6%2.0%3.1 $0.24 5/31/20255,340,000 shares $1.42 million -8.4%2.4%3 $0.27 5/15/20255,830,000 shares $1.54 million +31.0%2.6%3 $0.26 4/30/20254,450,000 shares $1.23 million -3.1%N/A2.7 $0.28 4/15/20254,590,000 shares $1.15 million -15.8%2.0%2.8 $0.25 3/31/20255,450,000 shares $1.07 million -3.4%2.4%3.2 $0.20 Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/15/20255,640,000 shares $2.54 million -11.3%2.5%3.3 $0.45 2/28/20256,360,000 shares $3.43 million -11.5%2.8%4 $0.54 2/15/20257,190,000 shares $4.16 million +4.5%3.2%4.3 $0.58 1/31/20256,880,000 shares $4.06 million +19.4%N/A3.4 $0.59 1/15/20255,760,000 shares $3.50 million +4.7%N/A2.7 $0.61 12/31/20245,500,000 shares $2.96 million +8.7%N/A2.6 $0.54 12/15/20245,060,000 shares $2.94 million -24.7%N/A2.8 $0.58 11/30/20246,720,000 shares $4.84 million -2.8%N/A4.1 $0.72 11/15/20246,910,000 shares $4.05 million +29.2%N/A4.7 $0.59 10/31/20245,350,000 shares $3.88 million -3.8%N/A4.5 $0.73 10/15/20245,560,000 shares $4.89 million -8.7%N/A3.5 $0.88 9/30/20246,090,000 shares $5.79 million -13.0%N/A3.6 $0.95 9/15/20247,000,000 shares $7.77 million +2.5%N/A3.9 $1.11 8/31/20246,830,000 shares $8.67 million -4.2%N/A3.7 $1.27 8/15/20247,130,000 shares $7.77 million No ChangeN/A3.3 $1.09 7/31/20247,130,000 shares $9.48 million +13.2%N/A3.5 $1.33 7/15/20246,300,000 shares $7.84 million +11.7%N/A4 $1.25 6/30/20245,640,000 shares $5.50 million +15.1%N/A3.6 $0.97 6/15/20244,900,000 shares $4.95 million +6.1%N/A3.3 $1.01 5/31/20244,620,000 shares $5.22 million +34.3%N/A2.8 $1.13 5/15/20243,440,000 shares $4.27 million -2.3%N/A2.5 $1.24 4/30/20243,520,000 shares $4.19 million +3.2%N/A2.3 $1.19 4/15/20243,410,000 shares $3.58 million +6.6%N/A1.7 $1.05 3/31/20243,200,000 shares $5.06 million +2.9%N/A1.7 $1.58 3/15/20243,110,000 shares $4.60 million +11.1%N/A1.7 $1.48 2/29/20242,800,000 shares $4.40 million -4.4%N/A1.6 $1.57 2/15/20242,930,000 shares $3.66 million -37.8%N/A2.1 $1.25 1/31/20244,710,000 shares $4.52 million -18.4%N/A3.8 $0.96 1/15/20245,770,000 shares $4.75 million +1.2%N/A9.3 $0.82 12/31/20235,700,000 shares $4.52 million -6.9%N/A9.6 $0.79Have You Seen This? Trump Schedules 'Stock Market Reset' For Sept. 30 (Ad)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions of Americans at risk of blackouts and could lead to a crisis "many times worse than 2008" if not fixed.Click here to see what this could soon mean for your portfolio. 12/15/20236,120,000 shares $2.75 million -0.8%N/A12 $0.45 11/30/20236,170,000 shares $3.09 million +3.0%N/A14.4 $0.50 11/15/20235,990,000 shares $3.00 million +2.4%N/A14.3 $0.50 10/31/20235,850,000 shares $3.16 million -12.6%N/A14.2 $0.54 10/15/20236,690,000 shares $4.39 million +12.1%N/A14.7 $0.66 9/30/20235,970,000 shares $4.66 million -1.3%N/A12.2 $0.78 9/15/20236,050,000 shares $4.91 million +3.1%N/A10.3 $0.81 8/31/20235,870,000 shares $4.58 million +1.9%N/A8.3 $0.78 8/15/20235,760,000 shares $4.49 million +0.4%N/A6.5 $0.78 7/31/20235,740,000 shares $5.41 million +1.4%3.9%6.5 $0.94 7/15/20235,660,000 shares $5.10 million -5.5%3.8%6.2 $0.90 6/30/20235,990,000 shares $5.54 million -19.6%4.1%6.3 $0.93 6/15/20237,450,000 shares $7.52 million -25.2%5.1%8.4 $1.01 5/31/20239,960,000 shares $10.16 million +8.7%6.8%11.6 $1.02 5/15/20239,160,000 shares $12.73 million +2.0%6.2%12.1 $1.39 4/30/20238,980,000 shares $12.75 million +19.9%6.2%12.5 $1.42 4/15/20237,490,000 shares $10.19 million +11.3%5.1%11.6 $1.36 3/31/20236,730,000 shares $7.34 million +28.7%4.6%11.9 $1.09 3/15/20235,230,000 shares $5.91 million +81.0%3.6%9.6 $1.13 2/28/20232,890,000 shares $5.12 million +1.8%2.0%6.5 $1.77 2/15/20232,840,000 shares $4.69 million +1.4%2.0%8.4 $1.65 1/31/20232,800,000 shares $5.24 million +3.3%1.9%6.4 $1.87 1/15/20232,710,000 shares $5.07 million -8.1%1.9%5.1 $1.87 12/30/20222,950,000 shares $4.31 million +7.7%2.0%5.6 $1.46 12/15/20222,740,000 shares $3.73 million -1.4%1.9%5.3 $1.36 11/30/20222,780,000 shares $6.03 million -26.1%1.9%5.3 $2.17 11/15/20223,760,000 shares $8.95 million +12.6%2.6%7.6 $2.38 10/31/20223,340,000 shares $4.74 million -10.0%2.3%7.9 $1.42 10/15/20223,710,000 shares $4.19 million -6.6%2.6%9.3 $1.13 9/30/20223,970,000 shares $4.27 million +7.0%2.8%13.5 $1.08 9/15/20223,710,000 shares $6.01 million +0.3%2.6%12.3 $1.62 8/31/20223,700,000 shares $7.33 million +1.7%2.6%11.6 $1.98 8/15/20223,640,000 shares $8.77 million -2.2%2.5%10.6 $2.41 7/31/20223,720,000 shares $6.88 million -7.9%2.6%9.7 $1.85 7/15/20224,040,000 shares $6.91 million +3.3%2.8%8.4 $1.71 6/30/20223,910,000 shares $6.65 million -4.6%2.7%6.9 $1.70 6/15/20224,100,000 shares $6.60 million -4.7%2.9%7.2 $1.61 5/31/20224,300,000 shares $6.19 million +0.5%3.1%6 $1.44 5/15/20224,280,000 shares $6.03 million -5.5%3.1%4.4 $1.41 4/30/20224,530,000 shares $7.79 million -2.2%3.3%4.5 $1.72 4/15/20224,630,000 shares $8.84 million -0.4%3.4%4.9 $1.91 3/31/20224,650,000 shares $9.58 million -10.2%3.4%4.8 $2.06 3/15/20225,180,000 shares $8.96 million -3.2%3.8%5.1 $1.73 2/28/20225,350,000 shares $13.91 million -2.4%3.9%5.4 $2.60 2/15/20225,480,000 shares $17.37 million +3.0%4.0%7.1 $3.17 1/31/20225,320,000 shares $15.53 million +4.1%3.9%6 $2.92 1/15/20225,110,000 shares $16.86 million +5.6%3.7%5.9 $3.30 12/31/20214,840,000 shares $18.15 million +29.4%3.5%5.8 $3.75 12/15/20213,740,000 shares $13.76 million +10.7%2.7%4.4 $3.68 11/30/20213,380,000 shares $14.03 million +8.3%2.5%3 $4.15Have You Seen This? Trump Schedules 'Stock Market Reset' For Sept. 30 (Ad)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions of Americans at risk of blackouts and could lead to a crisis "many times worse than 2008" if not fixed.Click here to see what this could soon mean for your portfolio. 11/15/20213,120,000 shares $13.57 million +5.8%2.3%1.6 $4.35 10/29/20212,950,000 shares $14.96 million -3.9%2.2%1.5 $5.07 10/15/20213,070,000 shares $16.36 million -8.4%2.2%1.6 $5.33 9/30/20213,350,000 shares $17.32 million -44.9%2.4%1.8 $5.17 9/15/20216,080,000 shares $32.83 million +47.9%4.4%3.3 $5.40 8/31/20214,110,000 shares $21.25 million +41.2%3.0%2.5 $5.17 8/13/20212,910,000 shares $11.61 million +8.2%2.1%4 $3.99 7/30/20212,690,000 shares $9.60 million -5.6%2.0%3.3 $3.57 7/15/20212,850,000 shares $10.66 million -5.0%2.1%3.3 $3.74 6/30/20213,000,000 shares $12.78 million -21.7%2.2%3.5 $4.26 6/15/20213,830,000 shares $15.86 million -2.5%2.8%4.2 $4.14 5/28/20213,930,000 shares $19.77 million -1.8%2.9%4.7 $5.03 5/14/20214,000,000 shares $18.24 million -0.7%N/A4.8 $4.56 4/30/20214,030,000 shares $23.29 million +5.0%N/A4.6 $5.78 4/15/20213,840,000 shares $19.35 million +27.2%N/A4.4 $5.04 3/31/20213,020,000 shares $15.25 million +64.1%N/A3.1 $5.05 3/15/20211,840,000 shares $10.08 million -0.5%N/A1.5 $5.48 2/26/20211,850,000 shares $10.99 million +22.5%N/A1.3 $5.94 2/12/20211,510,000 shares $10.01 million +4.9%N/A1 $6.63 1/29/20211,440,000 shares $7.89 million +8.3%N/A0.9 $5.48 1/15/20211,330,000 shares $8.11 million -64.1%N/A0.8 $6.10 12/31/20203,700,000 shares $20.02 million +31.2%N/A2 $5.41 12/15/20202,820,000 shares $11.56 million No ChangeN/A1.7 $4.10 11/30/20202,820,000 shares $13.85 million -5.1%N/A2.1 $4.91 11/15/20202,970,000 shares $14.82 million -35.0%N/A2.5 $4.99 10/30/20204,570,000 shares $20.70 million -29.0%N/A4.1 $4.53 10/15/20206,440,000 shares $51.20 million +21.1%N/A7 $7.95 9/30/20205,320,000 shares $42.45 million +8.6%N/A7.5 $7.98 9/15/20204,900,000 shares $49.39 million +50.8%N/A6.3 $10.08 ADAP Short Interest - Frequently Asked Questions What is Adaptimmune Therapeutics' current short interest? Short interest is the volume of Adaptimmune Therapeutics shares that have been sold short but have not yet been closed out or covered. As of August 15th, traders have sold 11,070,000 shares of ADAP short. Learn More on Adaptimmune Therapeutics' current short interest. Is Adaptimmune Therapeutics' short interest increasing or decreasing? Adaptimmune Therapeutics saw a increase in short interest in August. As of August 15th, there was short interest totaling 11,070,000 shares, an increase of 32.6% from the previous total of 8,350,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adaptimmune Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Adaptimmune Therapeutics: DURECT Corporation (1.58%), Precision BioSciences, Inc. (12.88%), ImageneBio, Inc. (0.43%), Clene Inc. (3.23%), Actinium Pharmaceuticals, Inc. (3.24%), PDS Biotechnology Corporation (4.12%), ImmuCell Corporation (0.23%), Karyopharm Therapeutics Inc. (26.88%), NRx Pharmaceuticals, Inc. (2.77%), Verrica Pharmaceuticals Inc. (2.77%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Lucid Group, Inc. ($8.00 billion), Spotify Technology ($5.48 billion), AppLovin Corporation ($5.11 billion), Reddit Inc. ($5.02 billion), Coinbase Global, Inc. ($3.99 billion), Charter Communications, Inc. ($3.89 billion), Live Nation Entertainment, Inc. ($3.18 billion), Seagate Technology Holdings PLC ($2.59 billion), ResMed Inc. ($2.55 billion), and Rocket Lab Corporation ($2.52 billion). View all of the most shorted stocks. What does it mean to sell short Adaptimmune Therapeutics stock? Short selling ADAP is an investing strategy that aims to generate trading profit from Adaptimmune Therapeutics as its price is falling. ADAP shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adaptimmune Therapeutics? A short squeeze for Adaptimmune Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ADAP, which in turn drives the price of the stock up even further. How often is Adaptimmune Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADAP, twice per month. The most recent reporting period available is August, 15 2025. More Short Interest Resources from MarketBeat Related Companies DRRX Short Interest Data DTIL Short Interest Data IMA Short Interest Data CLNN Short Interest Data ATNM Short Interest Data PDSB Short Interest Data ICCC Short Interest Data KPTI Short Interest Data NRXP Short Interest Data VRCA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADAP) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAP Stock Alerts